Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-3-20-16-40-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.85 million
Profitability
Miscellaneous
Employees148
Next Earnings DateN/A
OptionableNot Optionable
GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions
What is GENFIT S A/ADR's stock symbol?
GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."
What price target have analysts set for GNFT?
7 Wall Street analysts have issued 1-year target prices for GENFIT S A/ADR's shares. Their forecasts range from $25.47 to $58.00. On average, they anticipate GENFIT S A/ADR's share price to reach $47.89 in the next twelve months. This suggests a possible upside of 161.1% from the stock's current price. View Analyst Price Targets for GENFIT S A/ADR.
What is the consensus analysts' recommendation for GENFIT S A/ADR?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GENFIT S A/ADR.
Has GENFIT S A/ADR been receiving favorable news coverage?
Press coverage about GNFT stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GENFIT S A/ADR earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for GENFIT S A/ADR.
Who are some of GENFIT S A/ADR's key competitors?
Some companies that are related to GENFIT S A/ADR include Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS) and Twist Bioscience (TWST).
What other stocks do shareholders of GENFIT S A/ADR own?
Who are GENFIT S A/ADR's key executives?
GENFIT S A/ADR's management team includes the folowing people:
- Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
- Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
- Dr. Dean W. Hum, Chief Operating Officer (Age 57)
- Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
- Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)
When did GENFIT S A/ADR IPO?
(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.
Who are GENFIT S A/ADR's major shareholders?
GENFIT S A/ADR's stock is owned by many different of institutional and retail investors. Top institutional investors include SG Americas Securities LLC (0.06%), Jane Street Group LLC (0.04%) and US Bancorp DE (0.00%).
Which major investors are selling GENFIT S A/ADR stock?
GNFT stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC.
Which major investors are buying GENFIT S A/ADR stock?
GNFT stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC and US Bancorp DE.
How do I buy shares of GENFIT S A/ADR?
Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GENFIT S A/ADR's stock price today?
One share of GNFT stock can currently be purchased for approximately $18.34.
How big of a company is GENFIT S A/ADR?
What is GENFIT S A/ADR's official website?
How can I contact GENFIT S A/ADR?
GENFIT S A/ADR's mailing address is PARC EURASANTE 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]
MarketBeat Community Rating for GENFIT S A/ADR (NASDAQ GNFT)
MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote "Outperform" if you believe GNFT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days.
